• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0

Virus SARS-CoV-2 S protein (RBD, 319-541 aa) Monoclonal antibody, PBS Only

SARS-CoV-2 S protein (RBD, 319-541 aa) Monoclonal Antibody for WB,Neutralization,Indirect ELISA

Host / Isotype

Mouse / IgG1

Reactivity

Virus

Applications

WB,Neutralization,Indirect ELISA

Conjugate

Unconjugated

CloneNo.

1H3E9

Cat No : 67758-1-PBS

Print datasheet

Synonyms

COVID-19 RBD, RBD, SARS-CoV-2 Spike Glycoprotein (319-541 aa), spike protein

验证数据展示

  • WB analysis of Recombinant protein using 67758-1-Ig (same clone as 67758-1-PBS)

    WB analysis of Recombinant protein using 67758-1-Ig (same clone as 67758-1-PBS)

    Recombinant spike protein (RBD domain) were subjected to SDS PAGE followed by western blot with 67758-1-lg (SARS-CoV-2 Spike Glycoprotein (319-541 aa) antibody) at dilution of 1:10000 incubated at room temperature for 1.5 hours. This data was developed using the same antibody clone with 67758-1-PBS in a different storage buffer formulation.

  • Neutralization experiment of SARS-CoV-2 S protein (RBD, 319-541 aa) using 67758-1-Ig (same clone as 67758-1-PBS)

    Neutralization experiment of SARS-CoV-2 S protein (RBD, 319-541 aa) using 67758-1-Ig (same clone as 67758-1-PBS)

    Surrogate virus neutralization test of SARS-CoV-2 Spike Glycoprotein (319-541 aa) monoclonal antibody 67758-1-Ig using commercial kit. Briefly, RBD protein has been pre-coated on microplate, HRP labeled ACE2 protein and serial dose of 67758-1-Ig are added to the plate simultaneously and incubated for 1 hour at 37°C. The plate was then washed and signal was developed by adding chromogenic substrate followed by stop buffer. Signal strength was monitored at absorbance of 450nm. The IC50 is around 20 μg/mL. Please note that different IC50 will be obtained if different assays are used. Lyophilized format of this product is available. This data was developed using the same antibody clone with 67758-1-PBS in a different storage buffer formulation.

产品信息

67758-1-PBS targets SARS-CoV-2 S protein (RBD, 319-541 aa) in WB, Neutralization, Indirect ELISA applications and shows reactivity with Virus samples.

Tested Applications WB,Neutralization,Indirect ELISA Application Description
Tested Reactivity Virus
Immunogen SARS-CoV-2 S protein (RBD, 319-541 aa) fusion protein Ag30688 种属同源性预测
Host / Isotype Mouse / IgG1
Class Monoclonal
Type Antibody
Full Name SARS-CoV-2 Spike Protein
Synonyms COVID-19 RBD, RBD, SARS-CoV-2 Spike Glycoprotein (319-541 aa), spike protein
Calculated Molecular Weight 141 kDa
GenBank Accession NumberNC_045512
Gene Symbol COVID-19 S Protein
Gene ID (NCBI) 43740568
Conjugate Unconjugated
Form Liquid
Purification MethodProtein A purification
Storage Buffer PBS Only
Storage ConditionsStore at -80°C.

背景介绍

Coronaviruses (CoVs) infect human and animals and cause varieties of diseases, including respiratory, enteric, renal, and neurological diseases. CoV uses its spike protein to recognize ACE2 as its receptors and mediate membrane fusion and virus entry into host cells(PMID: 32221306). Each monomer of trimeric S protein is about 180 kDa, and contains two subunits, S1 and S2,S1 recognizes and binds to host receptors, and subsequent conformational changes in S2 facilitate fusion between the viral envelope and the host cell membrane(PMID: 19198616). Although the amino acid sequences of the S-glycoprotein were found to be different between the various HCoV, the structures showed high similarity, but the best 3D structural overlap shared by SARS-CoV and SARS-CoV-2, consistent with the shared ACE2 predicted receptor (PMID: 32522207). The spike protein of CoVs can be a target for vaccine and therapeutic development (PMID: 19198616).

Lyophilized format of this product is available.